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Glucagon-like peptide-1 analogues, liraglutide (Lira) and exenatide (Exn), are currently limited 
to subcutaneous injections in clinical protocols [1].  Due to several drawbacks accompanied 
with this invasive route, the development of oral delivery system is likely the most attractive 
choice. Among the various strategies having been developed to conquer the barriers limiting 
oral peptide delivery [2], [3], the encapsulation of GLP-1 analogues into nanosystems seem to 
be very promising strategy. Herein, the aim is to discuss the potential of designing polymeric 
nanosystem and self-emulsifying drug delivery system (SEDDS) for oral delivery of Lira and 
Exn. Due to the complexity and nanotoxicological concerns of nanopharmaceuticals in 
addition to the risks entailed with peptides formulation development, it is critical to focus on 
quality by design (QbD) application when developing nanocarriers encapsulating peptide 
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